GSK Mexico's General Director, Jorge Arévalo, revealed in a recent meeting that the pharmaceutical company, one of the most prominent globally, has significant growth plans for Mexico.
The corporation's priority assigned to the country was highlighted, with a strong strategic focus that encompasses clinical research.
GSK invests approximately $120 million pesos in research and development in Mexico, collaborating closely with public institutions.
GSK's key pharmacological areas include immunology (vaccines), infectious diseases, oncology, respiratory diseases, and HIV.
Significant advances in HIV treatment were highlighted, with medications that substantially improve quality of life and a future presentation of a long-acting compound that will require only one injection dose every three months.
The successful launch of the vaccine against respiratory syncytial virus (RSV) called Arexvy will result in estimated sales of £1 billion in 2023, consolidating Walmsley's position as a prominent figure in the industry.
The company has expansion plans in Mexico, focusing on adult vaccination. Awareness campaigns are anticipated regarding the importance of vaccinating against herpes zoster virus.
Additionally, a strong arrival of treatments related to RSV is expected, which is linked to pneumonia in babies and contagion in elderly adults. The National Committee for Epidemiological Surveillance has already issued an alert due to the high number of RSV cases in the present year.
With information from: El Heraldo de México.
Receive all industry news in our weekly Newsletter Dialéctica Científica.